New research evaluates clinical trials investigating post-acute COVID-19 syndrome treatment

In a recent article published in Clinical Microbiology and Infection, researchers reviewed all registered trials currently investigating potential treatment options for post-acute coronavirus disease 2019 (COVID-19) syndrome (PACS).

JCM, Free Full-Text

Frontiers Post-COVID-19 Syndrome: The Persistent Symptoms at the Post-viral Stage of the Disease. A Systematic Review of the Current Data

Paxlovid May Reduce Risk of Long Covid in Eligible Patients, Study Finds - The New York Times

Rationale, Design and Baseline Characteristics of the PARAGLIDE-HF Trial: Sacubitril/Valsartan vs Valsartan in HFmrEF and HFpEF With a Worsening Heart Failure Event - Journal of Cardiac Failure

Frontiers Therapeutic trials for long COVID-19: A call to action from the interventions taskforce of the RECOVER initiative

Researchers Race to Understand Long COVID in National Study, The Brink

Long covid outcomes at one year after mild SARS-CoV-2 infection: nationwide cohort study

Two Years into the COVID-19 Pandemic: Lessons Learned

Long COVID: pathophysiological factors and abnormalities of coagulation: Trends in Endocrinology & Metabolism

Postacute COVID-19 is Characterized by Gut Viral Antigen Persistence in Inflammatory Bowel Diseases - ScienceDirect